American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 814-823 , June 2007

Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis

  • Larry A. Greenbaum, MD, PhD

      Affiliations

    • Emory University and Children’s Healthcare of Atlanta, GA
    • Corresponding Author InformationAddress correspondence to Larry Greenbaum, MD, PhD, Emory University and Children’s Healthcare of Atlanta, GA 30322.
    • ,
  • Nadine Benador, MD

      Affiliations

    • University of California at San Diego, La Jolla
    • ,
  • Stuart L. Goldstein, MD

      Affiliations

    • Baylor College of Medicine/Texas Children’s Hospital, Houston, TX
    • ,
  • Ana Paredes, MD

      Affiliations

    • Miami Children’s Hospital, Miami, FL
    • ,
  • Joel Z. Melnick, MD

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • ,
  • Susan Mattingly, BSN

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • ,
  • Michael Amdahl, MS

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • ,
  • Laura A. Williams, MD, MPH

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • ,
  • Isidro B. Salusky, MD

      Affiliations

    • David Geffen School of Medicine at UCLA, Los Angeles, CA.

Received 31 October 2006 ,Accepted 13 March 2007.

References 

  1. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988;67:876–881
  2. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 1994;23:229–236
  3. Lopez H, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol. 1990;259:F432–F437
  4. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59:1187–1201
  5. Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med. 1978;298:238–242
  6. Bulla M, Delling G, Offermann G, et al. Renal bone disorders in children: Therapy with vitamin D3 or 1,25-dihydroxycholecalciferol. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1979;16:644–648
  7. Pierides AM, Ellis HA, Simpson W, Cook D, Kerr DN. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Clin Endocrinol (Oxf). 1977;7(suppl):S109–S116
  8. Postlethwaite RJ, Houston IB. Bone disease in children with chronic renal failure: Therapy with 1alpha-hydroxyvitamin D3. Clin Endocrinol (Oxf). 1977;7(suppl):S117–S124
  9. Ramirez JA, Goodman WG, Belin TR, Gales B, Segre GV, Salusky IB. Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol. 1994;267:E961–E967
  10. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984;74:2136–2143
  11. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992;19:532–539
  12. Greenbaum LA, Grenda R, Qiu P, et al. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol. 2005;20:622–630
  13. Ho M, Stablein DM. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report. Rockville, MD: NAPRTCS; 2002;
  14. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D (A role for increased sensitivity to calcium). J Clin Invest. 1989;83:1349–1355
  15. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest. 1986;78:1296–1301
  16. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S201
  17. Salusky IB, Kuizon BD, Belin TR, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int. 1998;54:907–914
  18. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth (High phosphorus directly stimulates PTH secretion in vitro). J Clin Invest. 1996;97:2534–2540
  19. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  20. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990;38:931–936
  21. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100–105
  22. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  23. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483–1490
  24. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427–1432
  25. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1364–1367
  26. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 1994;45:253–258
  27. Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–1808
  28. Salusky IB. Bone and mineral metabolism in childhood end-stage renal disease. Pediatr Clin North Am. 1995;42:1531–1550
  29. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66:2293–2299
  30. Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 2002;62:648–653
  31. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol. 2001;56:315–323
  32. Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005;16:2501–2508

 Originally published online as doi:10.1053/j.ajkd.2007.03.008 on May 4, 2007.

 Support: This study was funded by Abbott Laboratories. Potential conflicts of interest: Dr Williams, Dr Melnick, and Mr. Amdahl are employees of Abbott Laboratories, the manufacturer of paricalcitol.

PII: S0272-6386(07)00640-3

doi: 10.1053/j.ajkd.2007.03.008

American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 814-823 , June 2007

Article Tools

* Image Usage & Resolution